The data show prula-cel achieving immunosuppressant-free remission rates comparable to autologous CAR-T with a meaningfully better safety profile (no ICANS, no IEC-HS, no >Grade 2 CRS), supporting its potential as a differentiated off-the-shelf outpatient therapy. Key catalysts to watch: FDA alignment on pivotal expansion to non-renal SLE in Q4 2026, SSc data in H1 2027, and LN/SLE data update mid-2027. The single-arm pivotal design with CRR at 12 months as primary endpoint is a regulatory de-risking step, but enrollment pace and durability of responses beyond 12 months remain critical to monitor.
Price Chart
Executive Summary
Adicet Bio reported positive Phase 1 safety and efficacy data for prula-cel (formerly ADI-001), an allogeneic gamma delta CAR-T therapy, in 22 patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN). At 12 months, 50% of evaluable LN patients achieved complete renal response (CRR) and 54% of evaluable patients achieved DORIS remission, with all patients discontinuing immunosuppressants. The company aligned with the FDA on a single-arm pivotal study in LN and plans to initiate start-up activities in Q4 2026, with potential expansion to include non-renal SLE.
Key Facts
- 22 efficacy-evaluable patients (16 LN, 6 extra-renal SLE) with 6-21 months follow-up; 13 patients with ≥12 months follow-up
- 50% of evaluable LN patients achieved complete renal response (CRR) at 12 months
- 54% of evaluable patients achieved DORIS remission at 12 months
- All 12-month responses ongoing at 12-21 months except 1 patient with UPCR 0.65 g/g who remains off immunosuppressants
- All patients discontinued immunosuppressants; all but one tapered steroids to ≤5 mg prednisone equivalent
- No CRS > Grade 2, no DLTs, no IEC-HS, no ICANS; Grade 1-2 CRS in 25% of patients
- Infections reported in 54% of patients, Grade ≥3 in 8.3%
- 100% (22/22) of evaluable patients achieved undetectable CD19+ B cells with nave-dominant B-cell reconstitution
- FDA aligned on single-arm pivotal study in LN with primary endpoint of CRR at 12 months; expected to enroll double-digit number of patients, up to 90
- Company plans to initiate pivotal study start-up activities in Q4 2026; potential expansion to include non-renal SLE subject to FDA discussion in Q4 2026
- Approximately 35,000 LN patients and 35,000 non-renal SLE patients with organ/life-threatening disease in the U.S.
- Anticipated milestones: SSc clinical data update in H1 2027; LN/SLE clinical data update mid-2027; interim pivotal data in 2028; pivotal readout in 2029
Financial Impact
No financial data provided in filing; clinical-stage biotech with no approved products or reported revenue. Positive Phase 1 data and FDA alignment on pivotal path represent a significant de-risking event for the prula-cel program, potentially increasing the probability of regulatory success and commercial opportunity in a ~70K-patient U.S. addressable market.
Risk Factors
- Phase 1 data are preliminary with small sample size (22 efficacy-evaluable); results may not replicate in larger pivotal study
- Single-arm pivotal study design may face FDA scrutiny on sufficiency for approval
- Competition from autologous CAR-T, bispecifics, and in vivo CAR-T approaches in SLE/LN
- Company is pre-revenue and will require additional capital to fund pivotal study and operations
- Durability of remissions beyond 12-21 months of follow-up is not yet established
- Manufacturing scalability and cost for allogeneic off-the-shelf therapy at commercial scale not yet demonstrated
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001720580-26-000060 |
| Document: acet-ex99_2.htm | 0001720580-26-000060 |
| Document: acet-ex99_1.htm | 0001720580-26-000060 |
| Document: 0001720580-26-000060-index-headers.html | 0001720580-26-000060 |
| Document: 0001720580-26-000060-index.html | 0001720580-26-000060 |
| Document: 0001720580-26-000060.txt | 0001720580-26-000060 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC 13G | $4.03 | awaiting T+20 | — | $3.99 (−0.98%) |
Sep 28, 2026 28d ago | 8-K | $6.35 $3.94 | ▼ −37.95% | ▼ −37.92% | $3.99 (−37.17%) |
Sep 1, 2026 7w ago | 8-K | $9.26 $7.12 | ▼ −23.11% | ▼ −24.29% | $3.99 (−56.91%) |
May 20, 2026 22w ago | 10-K/A | $7.89 $8.23 | ▲ +4.31% | ▲ +3.98% | $3.99 (−49.43%) |
May 13, 2026 23w ago | 8-K | $8.41 $8.05 | ▼ −4.28% | ▼ −3.42% | $3.99 (−52.56%) |
Apr 8, 2026 28w ago | 144 | $6.86 $8.55 | ▲ +24.64% | ▲ +17.07% | $3.99 (−41.84%) |
Apr 7, 2026 28w ago | 144 | $6.55 $8.51 | ▲ +29.92% | ▲ +21.38% | $3.99 (−39.08%) |
Mar 24, 2026 30w ago | EFFECT | $6.69 $8.31 | ▲ +24.22% | ▲ +15.31% | $3.99 (−40.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers